Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31723252 | 1.00 | L3MBTL1 (0.39) | L3MBTL1KMT2AGAACSF1RSIGMAR1 | |
| SCHEMBL29454084 | 0.89 | EGFR (0.44) | L3MBTL1KMT2AGAACSF1REGFR | |
| SCHEMBL22232059 | 0.89 | EGFR (0.44) | L3MBTL1KMT2AGAACSF1REGFR | |
| SCHEMBL31723209 | 0.89 | EGFR (0.44) | L3MBTL1KMT2AGAACSF1REGFR | |
| SCHEMBL29454136 | 0.86 | CHKA (0.42) | KMT2AGAACSF1REGFRLMNA | |
| SCHEMBL29454192 | 0.85 | ABCG2 (0.36) | KMT2AGAAEGFRMAPK13MAPK12 | |
| SCHEMBL31723238 | 0.85 | ABCG2 (0.36) | KMT2AGAAEGFRMAPK13MAPK12 | |
| SCHEMBL22231907 | 0.85 | ABCG2 (0.36) | KMT2AGAAEGFRMAPK13MAPK12 | |
| SCHEMBL31723240 | 0.82 | ACHE (0.39) | CSF1RSIGMAR1EGFRSMN1; SMN2TSHR | |
| SCHEMBL22232258 | 0.82 | ACHE (0.39) | CSF1RSIGMAR1EGFRSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | claimed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | claimed |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | disclosed |
| EP-4647426-A2 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2025-11-12 | — | — | EP | disclosed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | H1-3, PRMT7, PFAS | L3MBTL1 881/4885KMT2A 438/4885GAA 1080/4885 |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | CBR1, CBR3, HCCS | L3MBTL1 2103/4885KMT2A 3264/4885GAA 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.